What Clabel Treats: Main Uses and Benefits

Clabel, with the active ingredient clarithromycin, is indicated for use where additional symptomatic support is needed during the treatment of infections. The main therapeutic uses involve managing infections such as those affecting the respiratory tract (including community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis), as well as pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections. In scenarios where additional management of discomfort is required, Clabel helps address symptom clusters that may become intense or disruptive. The medication is also commonly used, in combination with other agents, for managing Helicobacter pylori bacteria and for disseminated Mycobacterium avium complex (MAC) infections.

---

This medication provides supportive relief when symptoms related to physical discomfort, such as fever, pain, and inflammation, interfere with routine activities. It assists with maintaining functional stability during episodes of heightened discomfort.

Quick Fact: Relief for Symptoms related to physical discomfort (e.g., fever and inflammation)

Regulatory References

1. NIH DailyMed drug label

Who Can and Cannot Use Clabel?

The population eligibility for using Clabel (clarithromycin) is strictly defined by regulatory authorities and is classified by age, pre-existing health conditions, and hypersensitivity status. The official labeling specifies groups who are approved for use, those for whom use is restricted, and those who are absolutely contraindicated.

Contraindicated Populations

Clabel must not be used by individuals with a known hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic. It is also contraindicated in patients with a history of QT prolongation or ventricular arrhythmias. A specific comorbidity-based contraindication applies to patients with severe hepatic failure combined with renal impairment.

---

Restricted and Conditional Use

Population Group	Regulatory Status
Children under 12	Tablet formulation is not recommended; safety is not established for infants under six months.
Pregnancy/Lactation	Not recommended during pregnancy or breastfeeding unless strictly necessary.
Renal Impairment	Restricted use; dosage reduction is required for patients with creatinine clearance < 30 mL/min.
Cardiac Conditions	Requires caution in patients with severe cardiac insufficiency or conduction disturbances.

Interactions with other medicines and products

Clabel's official interaction profile is structured around its ability to inhibit the CYP3A4 enzyme system, which can significantly increase the systemic exposure of other co-administered medicines that are metabolized by this pathway. This action is documented in government regulatory labeling and dictates numerous restrictions on combined use.

Official Interaction Restrictions

The following categories of medicines are associated with documented interaction constraints:

• CYP3A4 Substrates with Narrow Therapeutic Index: Co-administration with specific drugs such as Pimozide, Ergotamine, Dihydroergotamine, and Colchicine is strictly contraindicated due to the high risk of serious and/or life-threatening adverse reactions, including cardiac arrhythmia and acute toxicity.
• HMG-CoA Reductase Inhibitors (Statins): The concurrent use of Lovastatin or Simvastatin is contraindicated. Clabel significantly increases the concentration of these statins, raising the risk of severe muscle toxicity, including rhabdomyolysis.
• Oral Anticoagulants and P-gp Substrates: Interactions with Warfarin and certain other anticoagulants require careful and frequent monitoring of coagulation parameters. Clabel is also known to inhibit the efflux transporter P-glycoprotein (P-gp), leading to increased exposure of P-gp substrates like Digoxin, necessitating dose review and monitoring for signs of toxicity.
• CYP3A Inducers: Medicinal products that induce CYP3A4 (e.g., Rifampicin, Phenytoin, St. John's Wort) can accelerate Clabel's own metabolism, resulting in subtherapeutic concentrations of Clabel and potentially reducing its effectiveness.

Inhibition of Bacterial Protein Synthesis

Clabel's active ingredient, Clarithromycin, acts by forming a reversible, high-affinity bond with the 23S ribosomal RNA (rRNA) component of the bacterial 50S ribosomal subunit. This precise molecular interaction physically blocks the Nascent Peptide Exit Tunnel (NPET) within the ribosome, functionally disabling the translational process. The resulting arrest of peptide elongation prevents the bacteria from synthesizing the structural and enzymatic proteins essential for growth and division. This cascade leads to a bacteriostatic effect that causes the functional suppression of the microbial population.

Sustained Antimicrobial Pressure and Limitations

The pharmacological effect is sustained by the drug’s primary metabolite, 14-(R)-hydroxyclarithromycin, which retains significant biological activity and utilizes the identical mechanism of ribosomal blockade. This dual action provides sustained antimicrobial pressure by maintaining the blockade of the 50S ribosomal subunit. The mechanism is compromised when bacteria develop defenses, primarily through ribosomal methylation of the 23S rRNA, which reduces the drug’s binding affinity and allows unrestricted bacterial proliferation.

Clabel's usage is based on established parameters to ensure standard administration and precise timing. The medicine, containing clarithromycin, is primarily supplied as a tablet for the oral route of administration. The active ingredient is also available as an oral suspension and in an Intravenous (IV) infusion form for specialized parenteral therapy.

Feature	Guideline
Route of administration	Oral (tablet/suspension) is primary; Intravenous (IV) available for parenteral therapy.
Dosing schedule (Adults)	250 mg or 500 mg every 12 hours for a course of 7 to 14 days.
Timing in relation to meals	Immediate-release tablets can be taken with or without food.
Preparation requirements	IV forms require dilution; oral suspension requires reconstitution with water.

The standard adult regimen for the immediate-release tablet form is 250 mg to 500 mg twice daily (every 12 hours). Treatment duration is typically 7 to 14 days, though specific multi-drug regimens, such as those for H. pylori infection, may require courses of 10 or 14 days. The immediate-release tablet may be taken with or without food, as its bioavailability is not significantly affected by meal intake.

For patients with severe renal impairment (creatinine clearance less than 30 mL/min), the total daily dosage must be reduced by half to account for reduced clearance. For pediatric patients under 12 years of age, the film-coated tablets are not the recommended form, and the oral suspension should be administered instead. If a dose is missed, it is advised not to take a double dose to compensate. The prescribed course duration must be completed entirely, as specified by the protocol.

Research Evidence / Overview of Studies for Clabel (Clarithromycin)

This summary is based on official research evidence, including randomized controlled trials (RCTs) and regulatory reviews, and describes what has been observed in clinical studies for Clabel. It is intended for informational purposes and does not offer medical advice or treatment recommendations.

---

Evidence for Respiratory Tract and Skin Infections

Research exploring its role in conditions such as Community-Acquired Pneumonia (CAP), Acute Bacterial Exacerbation of Chronic Bronchitis (AECB), and uncomplicated skin and soft-tissue infections primarily consists of short-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews and meta-analyses. These studies included both adult patients treated in outpatient settings and those requiring hospitalization for more acute conditions like CAP. The trials were designed to observe changes related to clinical response and outcomes reflecting daily functioning or activity level.

Studies report how symptoms evolved in the observed populations over the short duration of the treatment, typically 5 to 14 days. Outcomes measured included the rate at which clinical response was measured—for instance, the resolution of fever or cough—and the rate of bacteriological clearance. The findings describe patterns observed in the studies related to measured clinical response following the short course of medication. The evidence supporting the evaluation of Clabel for this indication is considered to be High Level, primarily derived from numerous Randomized Controlled Trials and systematic reviews.

Research on Pharyngitis and Tonsillitis

The evidence for treating acute pharyngitis and tonsillitis was applied in studies examining patient-reported experiences for conditions involving periods of heightened symptoms. These comparative trials focused on patients, including children and adolescents, where Clabel was evaluated in settings involving short, acute episodes. Studies monitored two main types of outcomes: the overall resolution of clinical symptoms and the rate of bacteriological clearance (elimination) of the specific bacteria, such as Group A Beta-Hemolytic Streptococcus.

Key Studies & References

1. Clarithromycin Oral Tablets [Official DailyMed Drug Label] (Reference for main uses and clinical trial summaries)
2. Macrolides (Erythromycin, Azithromycin, Clarithromycin) - General Drug Class Overview

Common questions about Clabel (FAQ)

---

Q: What happens if I forget to take a dose of Clabel?

According to official instructions, if a dose is missed, the official instructions indicate that it is taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is skipped entirely. Regulatory documents specifically caution against taking a double dose to compensate for a missed one.

Q: Why does the packaging for Clabel mention liver function?

Official labeling notes that Clabel is primarily processed by the liver, and caution is advised for people with pre-existing liver impairment. Transient elevations of liver enzyme values and other liver-related problems have been reported as documented adverse reactions in official safety profiles.

Q: Can Clabel be split or crushed if someone has trouble swallowing pills?

Whether the tablet can be altered depends on its specific formulation. Immediate-release, film-coated tablets may generally be dispersed or crushed and mixed with soft food or liquid. However, extended-release tablets are typically designed to be swallowed whole and must not be crushed, split, or chewed, as this can change how the medicine works in the body.

Q: Can I take Clabel while drinking alcohol?

Regulatory documentation does not list alcohol as a specific substance that is strictly contraindicated (forbidden) to take with Clabel. Nevertheless, health authorities commonly recommend limiting or avoiding alcohol intake in general while the body is recovering from an infection being treated by an antibiotic.

Q: What should I do if I think I'm having a rare side effect from Clabel?

Official safety bodies advise that any suspected adverse drug reactions, including effects that seem unusual or rare, are reported directly to your country's national drug authority. Reporting helps regulatory agencies continuously monitor the safety profile of the medicine.

Q: Is it common to feel tired when first starting Clabel?

The adverse reaction profile of Clabel includes fatigue (tiredness) and certain Central Nervous System (CNS) effects, such as dizziness and insomnia, among the reported effects in clinical studies. This is descriptive information found in the official safety profile.

Q: Why do some people say Clabel causes headaches?

Headache is consistently reported in regulatory documentation as one of the most frequently observed adverse reactions in clinical trials. This is a common effect documented in the official safety profile for the medicine.

Q: Will Clabel affect my ability to drive or operate machinery?

Official patient information notes that Clabel may cause feelings of dizziness or drowsiness. For this reason, caution is advised when driving or operating complex machinery until awareness of how the medicine may affect alertness is known.

Q: Are there any reported cases of Clabel affecting mood?

Post-marketing safety reports have included transient Central Nervous System (CNS) effects. These documented effects include symptoms such as anxiety, insomnia, confusion, and hallucinations, which are reported in regulatory documentation.

Q: Is Clabel available as a generic version?

Yes, Clabel's active ingredient, clarithromycin, is the generic name for the medicine. Multiple generic versions have been widely available following the expiration of the original patents and are approved by regulatory bodies.

Q: What are the ingredients in Clabel besides the main active component?

The official product labeling, such as in DailyMed, is legally required to list all ingredients. These include the active component and various inactive ingredients (excipients), which may consist of coloring agents, binding agents, and fillers used to form the tablet or suspension.

Q: Can Clabel affect fertility?

Official studies conducted in both preclinical (animal) and human settings have indicated that there is no evidence suggesting that Clabel's active ingredient reduces fertility in either men or women.

Q: Is Clabel known to cause any skin reactions?

The adverse reaction profile reported in regulatory documentation includes various skin reactions. These range from common mild skin eruptions to, in rare cases, severe reactions like Steven-Johnson Syndrome.

Q: Why is Clabel not approved for use in children?

Official documents state that the film-coated tablet formulation is generally not the recommended form for children under 12 years of age. Instead, an oral suspension product, which is specifically formulated for pediatric patients, is the indicated form for use in this age group.

Q: Does Clabel require special storage conditions?

Clabel tablets are required to be stored at room temperature, typically 20 C to 25 C, and should be protected from light. The official storage advice for the reconstituted oral suspension is different; it should not be refrigerated and must be used within 14 days.

Q: Is Clabel a treatment or a cure for the condition it treats?

Clabel is described in official documents as an antimicrobial agent and a semi-synthetic macrolide antibiotic. It is used for a specific course of treatment intended to suppress or eliminate bacterial infections rather than being designated as a cure for the underlying chronic condition.

Q: How does Clabel affect kidney function?

Official labeling notes that patients with severe renal impairment (poor kidney function) require an adjustment to the dose. The total daily dosage must be reduced by half because the body's ability to clear the medicine is decreased in this population.

Clabel (clarithromycin tablets) must be stored and disposed of according to official regulatory labeling to ensure product stability and safety.

Storage Requirements

Clabel must be kept at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The medicine must be protected from light and moisture and should remain in its tightly closed, original container to prevent degradation. As a mandatory safety requirement, Clabel must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Clabel should not be disposed of via wastewater or household trash unless following the specific guidance for non-take-back items. Regulatory documents instruct disposal through a drug take-back program if one is available. If not, the medicine should be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash.